文献速递白血病造血干细胞移植与细胞治疗

急性髓系白血病骨髓免疫特征与年龄、T细胞受体克隆性及生存相关

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival.
PubMed 文献 · Blood Adv · 2020-01-01

该研究用多重免疫组化和计算机图像分析比较了初诊AML、CML、B-ALL患者与对照的骨髓免疫表型,发现白血病亚型具有特异性免疫景观,AML可分为两个免疫集群且与年龄、T细胞受体克隆性和生存相关。低比例调节性T细胞和pSTAT1+cMAF-单核细胞是强化治疗AML患者无事件生存期更优的新生物标志物。

要点

  • 白血病亚型骨髓免疫景观各异,可准确分类AML、CML、B-ALL和对照。
  • AML存在两个免疫集群,差异体现在年龄、T细胞受体克隆性和生存上。
  • 低调节性T细胞和pSTAT1+cMAF-单核细胞与强化治疗AML更优无事件生存相关。

核心结论

  • 白血病亚型间免疫景观差异显著,提示疾病特异性免疫调节。
  • AML免疫微环境与临床参数相关,支持将免疫参数纳入疾病分类或风险分层。

研究设计与样本

  • 比较初诊AML(n=69)、CML(n=56)、B-ALL(n=52)患者与对照(n=12)的福尔马林固定石蜡包埋骨髓活检样本。
  • 采用多重免疫组化和计算机图像分析检测30种免疫表型标志物。

主要发现

  • 可准确分类AML(AUC=1.0)、CML(AUC=0.99)、B-ALL(AUC=0.96)和对照(AUC=1.0)。
  • 发现2个主要AML免疫集群,在年龄、T细胞受体克隆性和生存方面存在差异。
  • 低比例调节性T细胞和pSTAT1+cMAF-单核细胞是强化治疗AML患者无事件生存期更优的新生物标志物。
  • AML骨髓与外周血样本的免疫细胞表型不同。

关键数值与推荐

  • AML分类AUC=1.0,CML AUC=0.99,B-ALL AUC=0.96,对照AUC=1.0。
  • AML免疫集群分为2个主要集群,差异涉及年龄、T细胞受体克隆性和生存。

临床怎么用

  • 初诊AML骨髓免疫表型分析有助于亚型分类和免疫微环境评估。
  • 低调节性T细胞和pSTAT1+cMAF-单核细胞比例或可辅助强化治疗AML患者的预后判断。
  • 骨髓与外周血免疫表型存在差异,免疫评估应以骨髓样本为准。

局限性

  • 样本量有限(AML n=69,CML n=56,B-ALL n=52,对照 n=12)。
  • 为单中心回顾性分析,免疫参数与生存的关联需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The immunologic microenvironment in various solid tumors is aberrant and correlates with clinical survival. Here, we present a comprehensive analysis of the immune environment of acute myeloid leukemia (AML) bone marrow (BM) at diagnosis. We compared the immunologic landscape of formalin-fixed paraffin-embedded BM trephine samples from AML (n = 69), chronic myeloid leukemia (CML; n = 56), and B-cell acute lymphoblastic leukemia (B-ALL) patients (n = 52) at diagnosis to controls (n = 12) with 30 immunophenotype markers using multiplex immunohistochemistry and computerized image analysis. We identified distinct immunologic profiles specific for leukemia subtypes and controls enabling accurate classification of AML (area under the curve [AUC] = 1.0), CML (AUC = 0.99), B-ALL (AUC = 0.96), and control subjects (AUC = 1.0). Interestingly, 2 major immunologic AML clusters differing in age, T-cell receptor clonality, and survival were discovered. A low proportion of regulatory T cells and pSTAT1+cMAF- monocytes were identified as novel biomarkers of superior event-free survival in intensively treated AML patients. Moreover, we demonstrated that AML BM and peripheral blood samples are dissimilar in terms of immune cell phenotypes. To conclude, our study shows that the immunologic landscape considerably varies by leukemia subtype suggesting disease-specific immunoregulation. Furthermore, the association of the AML immune microenvironment with clinical parameters suggests a rationale for including immunologic parameters to improve disease classification or even patient risk stratification.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Brück O, Dufva O, Hohtari H, et al. Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. Blood Adv. 2020. PMID: 31968078. doi:10.1182/bloodadvances.2019000792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。